Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05298033 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT05298033 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 32 participants.
The verdict
NCT05298033, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase 2A clinical trial designed to test the pro-melanogenic and anti-inflammatory role of phosphodiesterase-4 inhibitors (PDE4i), alone and in combination with active narrow band UVB (NBUVB), in vitiligo lesions. This is a double-blind, randomized controlled trial (RCT) with six study arms. The goal is for 64 participants to be recruited and complete the study.
Interventions
- DRUG Vehicle
- DRUG Crisaborole 2 % Topical Ointment
- DRUG PF-07038124 0.01% topical ointment
- DEVICE NBUVB phototherapy
- DEVICE Sham phototherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05298033
The ClinicalTrials.gov registry entry for NCT05298033 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vehicle is the first listed.
NCT05298033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05298033 about?
NCT05298033 is a clinical study titled "Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo". This is a phase 2A clinical trial designed to test the pro-melanogenic and anti-inflammatory role of phosphodiesterase-4 inhibitors (PDE4i), alone and in combination with active narrow band UVB (NBUVB), in vitiligo lesions. This is a double-blind, randomized controlled trial (RCT) with six study arm...
What is the current status of trial NCT05298033?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-09-07. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT05298033?
The interventions under investigation include: Vehicle (DRUG), Crisaborole 2 % Topical Ointment (DRUG), PF-07038124 0.01% topical ointment (DRUG), NBUVB phototherapy (DEVICE), Sham phototherapy (DEVICE).
Who is sponsoring clinical trial NCT05298033?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.